Sanofi's expenditure on research and development 2008-2022

In 2022, biopharmaceutical company Sanofi spent approximately 6.7 billion U.S. dollars on research and development. Sanofi’s R&D expenditures have increased with each consecutive year since 2013, but dropped between 2019 and 2020.

The French pharmaceutical giant

Sanofi Société Anonyme (or Sanofi S.A.), headquartered in Paris, France, is active in more than one hundred countries worldwide, with a global workforce of around 91 thousand people in 2022. The company generates most of its revenue from its pharmaceuticals segment, while over seven billion U.S. dollars were earned through the company’s prosperous vaccines segment. Sanofi’s vaccine segment is a global leader in the world of vaccines. In 2022, this business segment generated 2.3 billion U.S. dollars specifically through vaccines for polio, pertussis (whooping cough), and Hib (Haemophilus influenzae type b).

Clinical trials

A clinical trial or study is conducted in order to uncover whether a particular compound is efficient and safe to use for the treatment of people. It is a lengthy process that can take several years. Such trials are also necessary to get a vaccine or a drug approved for marketing purposes.